DURABLE
Regimen
- Experimental
- durvalumab + anlotinib maintenance
- Control
- durvalumab maintenance
Population
Extensive-stage small-cell lung cancer without progression after four cycles platinum chemotherapy + durvalumab
Key finding
Protocol publication only — primary efficacy results not yet indexed on PubMed (results presented at conference)
Source: PMID 37947242
Timeline
Guideline citations
- CSCO SCLC 2025 (p.67)⚠️ OCR source